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Theaimofthisstudywastoinvestigatethetherapeuticeﬃcacyofα-radioimmunotherapyofovariancancerinmiceusingdiﬀerent
fractionated treatment regimens. The study was performed using the monoclonal antibody MX35 F(ab
 )2 labeled with the α-
particle emitter 211At. Methods. Nude mice were intraperitoneally inoculated with ∼1 × 107 cells of the cell line NIH:OVCAR-3.
Four weeks later 6 groups of animals were given 400kBq
211At-MX35 F(ab
 )2 as a single or as a repeated treatment of up to 6 times
(n = 18 in each group). The fractionated treatments were given every seventh day. Control animals were treated with unlabeled
MX35F(ab
 )2 (n = 12).Eightweeksposttreatmenttheanimalsweresacriﬁcedandthepresenceofmacro-andmicroscopictumors
and ascites was determined. Results. The tumor-free fractions (TFFs) of the animals, deﬁned as the fraction of animals with no
macro- and microtumors and no ascites, were 0.17, 0.11, 0.39, 0.44, 0.44, and 0.67 when treated with 400kBq
211At-MX35 F(ab
 )2
once or 2, 3, 4, 5, or 6 times, respectively. Repeated treatment 3 times or more resulted in a signiﬁcantly higher (P<. 05) TFF
than compared to treatment once or twice. The presence of ascites decreased from 15 out of 18 animals in the group given only
one treatment to zero for the 2 groups given 5 or 6 fractions. Treatment with unlabeled MX35 F(ab
 )2 resulted in a TFF of zero.
Conclusion. Weekly repeated intraperitoneal injections of tolerable amounts of activity of 211At-MX35 F(ab
 )2 of up to 6 times
produced increased therapeutic eﬃcacy without observed toxicity, indicating a potential increase of the therapeutic index.
1.Introduction
Ovarian cancer frequently recurs on the peritoneal surface
from remaining micrometastatic growth in spite of debulk-
ing surgery and systemic chemotherapy. External abdominal
radiotherapy has proven unsuccessful due to absorbed dose
limitations of normal tissues. Therefore, adjuvant locore-
gional treatment with intraperitoneal targeted ligands could
be decisive in the treatment of remaining micrometastatic
disease. Several studies have been performed on radioim-
munotherapy (RIT) of ovarian cancer, mostly mAbs labeled
with 90Ya n d 131I, in animals [1–6] and humans [7–12]. The
β-emitting radionuclides however have too long a range for
eﬀectively treating microscopic tumors. Thus we believe it
is important to continue our investigations of the eﬃcacy
of mAbs labeled with α-particle emitters when treating
microscopic disease on the peritoneum [13]. In this study,
as in a series of earlier studies [14–19], we used the α-
particle emitter 211At, with a half-life of 7.21 hours, a mean
range in tissue of ∼62μm, and a mean linear energy transfer
(LET) of ∼111keV/μm. The half-life of this radionuclide
makes it ideal for local treatment as the target cells are easily
reached while the transfer of the radioimmunocomplex to
the systemic circulation is delayed. The short range ensures
a signiﬁcant absorbed dose in microscopic tumors or even
single cells. The high LET, together with the high relative
biological eﬀectiveness (RBE) of the α-particles necessitating
only a few hits to devitalize the cell, indicates that only a
small number of 211At-atoms have to be targeted to each cell
[20, 21].
In this study we used the monoclonal antibody (mAb)
MX35 F(ab
 )2, which recognizes the sodium dependant
phosphate transport protein 2b (NaPi2b) of ∼90kDa on
ovarian cancer cells. We used an animal model mimicking2 Journal of Oncology
the clinical situation with intraperitoneal RIT. The intraperi-
toneal approach allows a high absorbed dose to nonvas-
cularized peritoneal tumor cells with low myelotoxicity as
the clearance rate from the peritoneal cavity to the systemic
circulation delays systemic exposure.
Fractionated external radiotherapy widens the therapeu-
tic index compared to using a single fraction and higher
absorbed doses can be delivered with acceptable toxicity. We
hypothesize that this could be true for internal α-RIT.
2.MaterialsandMethods
2.1. Radionuclide. 211At was produced by the
209Bi(α,
2n) 211At reaction in a cyclotron (Scanditronix MC32 at
the PET and Cyclotron Unit, Rigshospitalet, Copenhagen,
Denmark) by irradiating a
209Bi target with 28-MeV α-
particles. The 211At was isolated using a dry-distillation
procedure [22].
2.2. Monoclonal Antibodies. MX35 is a murine IgG1-class
mAb, developed and characterized at the Memorial Sloan-
Kettering Cancer Center (MSKCC), Ny, USA. MX35 is
directed towards the sodium dependant phosphate transport
protein 2b (NaPi2b) of ∼90 kDa on OVCAR-3 cells [23]
and is expressed strongly and homogeneously on ∼90% of
human epithelial ovarian cancers [24]. A batch of MX35
F(ab
 )2, produced by Strategic BioSolutions (Newark, USA)
for clinical use, was provided by MSKCC.
2.3. Antibody Labeling. MAbs were labeled with 211At
using the intermediate labeling reagent m-MeATE (N-
succinimidyl 3-(trimethylstannyl)benzoate) [25]. Brieﬂy, to
a dry residue of 211At (50–100MBq) was added a mixture of
m-MeATE and N-iodosuccinimide in methanol: 1% acetic
acid. This solution was then incubated for 20 minutes at
room temperature and the labeling reaction was stopped
by adding sodium ascorbate. The mAb MX35 F(ab
 )2
was then added to the labeling mixture and conjugation
was allowed to proceed for 20 minutes. Finally, the mAb
fraction was isolated using a NAP-5 column (Amersham
Biosciences, Uppsala, Sweden), resulting in a speciﬁc activity
of 120kBq/μg, that is, 1 labeled mAb out of ∼1200mAbs.
2.4. Cell Line. The cell line OVCAR-3 (NIH:OVCAR-3,
ATCC, USA) was used [26]. The cell line was obtained from
the American Type Culture Collection, Rockville, MD, USA.
The cells were cultured in T-75 culture ﬂasks at 37
◦Ci n
a humidiﬁed atmosphere of 95% O2/5% CO2 with RPMI-
1640 cell culture medium supplemented with 10% fetal calf
serum, 1% L-glutamine, and 1% penicillin-streptomycin.
2.5. Immunoreactivity of Antibodies. After conjugation, the
immunoreactivity of the mAbs was analyzed in vitro by
determination of the immunoreactive fraction, representing
conditions of inﬁnite antigen excess, which was derived from
a plot of the total applied radioactivity divided by cell-
bound radioactivity as a function of the inverse of the cell
concentration [27].
2.6. Animals. We used 120 female, nude Balb/c nu/nu mice
(Charles River Laboratories International Inc., Wilmington,
MA, USA) in this study. The animals were housed at 22
◦C
and 50%–60% humidity with a light/dark cycle of 12 hours.
They were given autoclaved standard pellets and water ad
libitum. All the experiments were approved by the Ethics
Committee of the University of Gothenburg.
2.7. In Vivo Procedures and Study Groups. At the age of
5weeks all mice were intraperitoneally inoculated with
∼1 × 107 OVCAR-3 cells suspended in 0.2mL saline. Four
weeks after cell inoculation the animals were divided into
7 groups. The animals in groups 1–6 were intraperitoneally
injected with 400kBq 211At-MX35 F(ab
 )2 in 1mL saline
as a single or as a weekly treatment of 2, 3, 4, 5, or 6
times, respectively (n = 18 in each group). As controls
(group 7), animals were treated once with unlabeled MX35
F(ab
 )2 (n = 12). All the animals were thereafter weighed
weekly. Eight weeks after the last treatment occasion for
eachgrouptheanimalsweresacriﬁcedbycervicaldislocation
and dissected. The abdominal cavity was opened and the
presence of ascites and macroscopic lesions was judged as
“yes” or “no”. Peritoneal biopsies were taken from the upper
left quadrant since tumor propagation is most frequently
seen in this area. Suspected lesions were also biopsied. All
biopsies were processed for light microscopy and judged as
“yes” or “no.” Animals dissected and judged were blinded
from knowledge of exposure conditions. Diﬀerences in TFF
and weight between the diﬀerent study groups were tested
using a 2-sample test for equality of proportions.
3. Results
The radiochemical yields were 30%–40% and the radio-
chemical purity was over 95% as determined by methanol
precipitation and gel-permeability chromatography. The
immunoreactivity measurements of the 211At-MX35 F(ab
 )2
a n dO V C A R - 3c e l l sg a v ea ni m m u n o r e a c t i v ef ra c t i o no f0 . 9 5 .
The TFFs of the study groups, deﬁned as the fraction of
animals with no macro- and microtumors and no ascites,
were 0.17, 0.11, 0.39, 0.44, 0.44, and 0.67 when treated with
400kBq 211At-MX35 F(ab
 )2 as a single or as a repeated
treatment regimen of 2, 3, 4, 5, or 6 times, respectively
(Table 1) .R e p e a t e dt r e a t m e n to f3 ,4 ,5 ,o r6t i m e sr e s u l t e d
in a signiﬁcantly higher (P < .05) TFF than that compared
to 1 or 2 treatment. The presence of ascites decreased from
15 out of 18 animals in the group given only one treatment
t oz e r of o rt h e2g r o u p sg i v e n5o r6r e p e a t e dt r e a t m e n t s .
The presence of tumors did not decrease as drastically as the
presenceofasciteswhenthenumberoftreatmentsincreased.
Treatment with unlabeled MX35 F(ab
 )2 resulted in a TFF of
zero.
The ﬁndings on the peritoneal biopsies at the time of
dissection revealed both larger tumor cell clusters of several
millimetresindiameteraswellasclustersconsistingofonlya
fewtumorcells.Thetumorcellsweresometimesonlyloosely
adhered to the peritoneum but had sometimes penetrated
under the mesothelial cell layer.Journal of Oncology 3
Table 1: Study groups and number of mice with macroscopic and microscopic tumors and ascites.
Group n Treatment Number of treatments Macroscopic tumors Microscopic tumors Ascites TFF
∗
1 18 400
†kBq
211At-MX35 F(ab
 )2 in PBS
‡ 1 11/18 15/18 15/18 0.17
2 18 400
†kBq
211At-MX35 F(ab
 )2 in PBS
‡ 2 16/18 16/18 8/18 0.11
3 18 400
†kBq
211At-MX35 F(ab
 )2 in PBS‡ 3 11/18 11/18 5/18 0.39
4 18 400
†kBq
211At-MX35 F(ab
 )2 in PBS
‡ 4 10/18 10/18 1/18 0.44
5 18 400
†kBq
211At-MX35 F(ab
 )2 in PBS
‡ 5 10/18 10/18 0/18 0.44
6 18 400
†kBq
211At-MX35 F(ab
 )2 in PBS
‡ 6 6/18 6/18 0/18 0.67
7 12 MX35 F(ab
 )2 in PBS 1 12/12 12/12 10/12 0
∗TFF : tumor-free fraction (i.e., fraction of animals with no macro- and microscopic tumors and no ascites). Injected activities were †400 ± 14 kBq (mean
± SEM). ‡PBS : phosphate-buﬀered saline. The presence of macroscopic tumors and ascites was assesed by careful ocular inspection during dissection 2mo
after the last administration of the radioimmunocomplex. Microscopic tumor growth was assessed by conventional histopathology. Judgements were blinded
from treatment information.
The general condition of the animals seemed to be
unaﬀected by the diﬀerent treatment regimens, although the
weights of the control animals were signiﬁcantly higher (P
< .05) than those of the animals given diﬀerent regimens
of 211At-MX35 F(ab
 )2 (groups 1–6), due to the ascites
production. No mutually signiﬁcant diﬀerence (P > 0.5) in
weight between the groups given diﬀerent regimens of 211At-
MX35 F(ab
 )2 c o u l db ed e t e c t e da n dn od e a t h so c c u r r e d
during followup.
4. Discussion
Fractionated radiotherapy in humans results in an increased
therapeutic eﬃcacy as compared to single doses and allows
for increased total absorbed dose delivered to the target
area. Mimicking such fractionation using RIT presents chal-
lenges with respect to physical half-lives and biodistribution.
Reasons why fractionated RIT would appear promising
are the possibility of reducing the systemic toxicity and
hence increasing the maximum tolerated activity, achieving
a more uniform absorbed dose distribution in the tumor,
and increasing the therapeutic index. We have in a previous
animal study found signiﬁcantly less myelotoxicity dividing
the injected activity into 3 fractions, with only a minor
decrease in therapeutic eﬃcacy [28]. In that study we also
discussed the potential risk of treatment interruption in
the human situation due to human antimouse antibody
(HAMA) response. However, in our recently published
p h a s eIs t u d yi nw h i c hw eu s e daf r a g m e n t e dI g G 1m A b
(MX35 F(ab
 )2) we could not detect any signs of any
HAMA response, indicating a low probability for an HAMA
responses in potential future fractionated clinical RIT treat-
ments [29]. In the present study we chose an activity well
tolerated as a single injection (400kBq), with a white blood
cell recovery approximately within a week, to be repeated
weekly for up to 6 times, that is, a total activity of up to
2400kBq, not tolerated as a single injection [20]. An interval
of 7 days was chosen from the bone marrow recovery data
[28]a sw e l la sf r o ml o g i s t i c s ,t h a ti s ,aw e e k l yd e l i v e r y
of 211At. The rationale for choosing the fragmented mAb
instead of the whole IgG in this study is due to 4 facts. (i) The
fragmented mAb was the only clinical grade version of the
mAb available at the time of the study; (ii) we have received
an approval by the Swedish Medical Products Agency for
carry through a phase I study with this fragmented mAb;
(iii) we believe that the diﬀusion into tumors using the
fragmented mAb is higher than compared to whole IgG; (iv)
We believe that the immunogenicity of the fragmented mAb
is lower than the whole IgG, reducing the risk for HAMA
response, especially if repeated treatments are considered in
the future.
In the series of experiments in this paper the eﬃcacy
expressed as the tumor-free fraction (TFF) was less than in
previous studies from our group [14–19], but a signiﬁcant
total activity and TFF relation were shown without any
signs of toxicity. The diﬀerence in the eﬃcacy between the
studies probably reﬂects varying proliferation of the injected
cells resulting in diﬀerent sizes of the tumor deposits at the
time of treatment, that is, 4 weeks postinjection. Since the
α-particle track length is limited to 60–70μm the size of
the tumor cell clusters is crucial. In an earlier study [19]
tumor dimensions were measured and the largest clusters at
4weeks postinoculation were ∼95μm, actually exceeding the
α-particle path length. A signiﬁcant peeling of the outermost
cell layers of the tumor cell clusters and/or a uniform
absorbed dose distribution does not seem probable since
∼1/3 of the animals were not free of tumors in spite of up
to 6 treatment fractions. In the interval of 400–1200kBq in
our earlier preclinical studies the TFF was not correlated
with the administered activity. This could be explained by
the saturation of the antigenic sites, which—according to the
dynamic compartmental model introduced in one of those
studies [17]—occurs within a few hours after the injection,
resulting in a similar absorbed dose for those activity levels.
In our recently published phase I study on women in
clinical complete remission after ovarian cancer occurrence
we disclosed no marrow toxicity after an intraperitoneal
injection of ∼200MBq 211At-MX35 F(ab
 )2 in 1L, which is
in accordance with a low absorbed dose to the bone marrow
derived from biokinetic data [29]. This, together with a
low probability for HAMA response discussed above, could
indicate a possibility of using a fractionated regimen in a
phase II study now under planning.
In conclusion, weekly repeated intraperitoneal injections
of tolerable amounts of activity of 211At-MX35 F(ab
 )2 of
up to 6 times produced increased eﬃcacy without observed4 Journal of Oncology
toxicity, indicating a potential increase of the therapeutic
index.
Acknowledgments
This work was conducted at The Sahlgrenska Academy at the
University of Gothenburg and was supported by grants from
the Swedish Cancer Society (no. 3548) and the King Gustaf V
Jubilee Clinic Research Foundation in Gothenburg, Sweden.
References
[1] S. A. McQuarrie, J. R. Mercer, A. Syme, M. R. Suresh, and G.
G. Miller, “Preliminary results of nanopharmaceuticals used
in the radioimmunotherapy of ovarian cancer,” Journal of
Pharmacy & Pharmaceutical Sciences, vol. 7, pp. 29–34, 2004.
[2] M. L. Janssen, W. Pels, L. F. Massuger, et al., “Intraperitoneal
radioimmunotherapy in an ovarian carcinoma mouse model:
eﬀect of the radionuclide,” International Journal of Gynecolog-
ical Cancer, vol. 13, no. 5, pp. 607–613, 2003.
[ 3 ]P .E .B o r c h a r d t ,S .M .Q u a d r i ,R .S .F r e e d m a n ,a n dH .
M. Vriesendorp, “Intraperitoneal radioimmunotherapy with
human monoclonal IGM in nude mice with peritoneal
carcinomatosis,”CancerBiotherapyandRadiopharmaceuticals,
vol. 15, no. 1, pp. 53–64, 2000.
[4] C. Grana, M. Bartolomei, D. Handkiewicz, et al., “Radioim-
munotherapy in advanced ovarian cancer: is there a role for
pre-targeting with 90Y-biotin?” Gynecologic Oncology, vol. 93,
no. 3, pp. 691–698, 2004.
[5] R. F. Meredith, R. D. Alvarez, E. E. Partridge, et al., “Intraperi-
tonealradioimmuno-chemotherapyofovariancancer:aphase
Is t u d y , ”Cancer Biotherapy and Radiopharmaceuticals, vol. 16,
pp. 305–315, 2001.
[6] M.-A. Mahe, P. Fumoleau, M. Fabbro, et al., “A phase II
study of intraperitoneal radioimmunotherapy with iodine-
131-labeled monoclonal antibody OC-125 in patients with
residual ovarian carcinoma,” Clinical Cancer Research, vol. 5,
no. 10, supplement, pp. 3249–3253, 1999.
[7] A.A.Epenet os,V .H ir d,H.Lambert,P .M ason,andC.C oult er ,
“Long term survival of patients with advanced ovarian cancer
treated with intraperitoneal radioimmunotherapy,” Interna-
tional Journal of Gynecological Cancer, vol. 10, supplement 1,
pp. 44–46, 2000.
[8] R. D. Alvarez, E. E. Partridge, M. B. Khazaeli, et al., “Intraperi-
toneal radioimmunotherapy of ovarian cancer with 177Lu-
CC49: a phase I/II study,” Gynecologic Oncology, vol. 65, no.
1, pp. 94–101, 1997.
[9] R. D. Alvarez, W. K. Huh, M. B. Khazaeli, et al., “A phase I
study of combined modality 90Yttrium-CC49 intraperitoneal
radioimmunotherapy for ovarian cancer,” Clinical Cancer
Research, vol. 8, no. 9, pp. 2806–2811, 2002.
[10] J. S. W. Stewart, V. Hird, D. Snook, et al., “Intraperitoneal
yttrium-90-labeled monoclonal antibody in ovarian cancer,”
Journal of Clinical Oncology, vol. 8, no. 12, pp. 1941–1950,
1990.
[11] R. H. Verheijen, L. F. Massuger, B. B. Benigno, et al.,
“Phase III trial of intraperitoneal therapy with yttrium-90-
labeledHMFG1murinemonoclonalantibodyinpatientswith
epithelial ovarian cancer after a surgically deﬁned complete
remission,”JournalofClinicalOncology,vol.24,no.4,pp.571–
578, 2006.
[12] A. L. Oei, R. H. Verheijen, M. V. Seiden, et al., “Decreased
intraperitoneal disease recurrence in epithelial ovarian cancer
patients receiving intraperitoneal consolidation treatment
with yttrium-90-labeled murine HMFG1 without improve-
ment in overall survival,” International Journal of Cancer, vol.
120, no. 12, pp. 2710–2714, 2007.
[13] H. Andersson, J. Elgqvist, G. Horvath, et al., “Astatine-211-
labeled antibodies for treatment of disseminated ovarian
cancer: an overview of results in an ovarian tumor model,”
Clinical Cancer Research, vol. 9, no. 10, pp. 3914–3921, 2003.
[14] H. Andersson, S. Lindegren, T. B¨ ack, L. Jacobsson, G. Leser,
and G. Horvath, “Radioimmunotherapy of nude mice with
intraperitoneally growing ovarian cancer xenograft utiliz-
ing 211At-labelled monoclonal antibody MOv18,” Anticancer
Research, vol. 20, no. 1, pp. 459–462, 2000.
[15] H. Andersson, S. Lindegren, T. B¨ ack, L. Jacobsson, G. Leser,
and G. Horvath, “The curative and palliative potential of the
monoclonalantibodyMOv18labelledwith 211At in nude mice
with intraperitoneally growing ovarian cancer xenografts: a
long-term study,” Acta Oncologica, vol. 39, no. 6, pp. 741–745,
2000.
[16] H. Andersson, S. Palm, S. Lindegren, et al., “Comparision of
the therapeutic eﬃcacy of 211At- and 131I-labelled monoclonal
antibody MOv18 in nude mice with intraperitoneal growth of
human ovarian cancer,” Anticancer Research, vol. 21, no. 1, pp.
409–412, 2001.
[17] J. Elgqvist, H. Andersson, T. B¨ ack, et al., “Therapeutic
eﬃcacy and tumor dose estimations in radioimmunotherapy
ofintraperitoneallygrowingOVCAR-3cellsinnudemicewith
211At-labeled monoclonalantibodyMX35,”JournalofNuclear
Medicine, vol. 46, no. 11, pp. 1907–1915, 2005.
[18] J. Elgqvist, H. Andersson, P. Bernhardt, et al., “Admin-
istered activity and metastatic cure probability during
radioimmunotherapy of ovarian cancer in nude mice with
211At-MX35F(ab
 )2,” International Journal of Radiation Oncol-
ogy Biology Physics, vol. 66, no. 4, pp. 1228–1237, 2006.
[19] J. Elgqvist, H. Andersson, T. B¨ ack, et al., “α-
radioimmunotherapy of intraperitoneally growing OVCAR-3
tumors of variable dimensions: outcome related to measured
tumor size and mean absorbed dose,” Journal of Nuclear
Medicine, vol. 47, no. 8, pp. 1342–1350, 2006.
[20] J. Elgqvist, P. Bernhardt, R. Hultborn, et al., “Myelotoxicity
and RBE of 211At-conjugated monoclonal antibodies com-
paredwith 99mTc-conjugatedmonoclonalantibodiesand 60Co
irradiation in nude mice,” Journal of Nuclear Medicine, vol. 46,
no. 3, pp. 464–471, 2005.
[21] T. B¨ ack, H. Andersson, C. R. Divgi, et al., “211At
radioimmunotherapy of subcutaneous human ovarian
cancer xenografts: evaluation of relative biologic eﬀectiveness
of an α-emitter in vivo,” Journal of Nuclear Medicine, vol. 46,
no. 12, pp. 2061–2067, 2005.
[22] S. Lindegren, T. B¨ ack, and H. J. Jensen, “Dry-distillation of
astatine-211 from irradiated bismuth targets: a time-saving
procedure with high recovery yields,” Applied Radiation and
Isotopes, vol. 55, no. 2, pp. 157–160, 2001.
[23] B. W. Yin, R. Kiyamova, R. Chua, et al., “Monoclonal antibody
MX35 detects the membrane transporter NaPi2b (SLC34A2)
in human carcinomas,” Cancer Immunity, vol. 8, pp. 3–11,
2008.
[24] S. C. Rubin, L. Kostakoglu, C. Divgi, et al., “Biodistribution
and intraoperative evaluation of radiolabeled monoclonal
antibody MX 35 in patients with epithelial ovarian cancer,”
Gynecologic Oncology, vol. 51, no. 1, pp. 61–66, 1993.Journal of Oncology 5
[25] S. Lindegren, H. Andersson, T. B¨ ack, L. Jacobsson, B. Karls-
son, and G. Skarnemark, “High-eﬃciency astatination of
antibodies using N-iodosuccinimide as the oxidising agent
in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate,”
Nuclear Medicine and Biology, vol. 28, no. 1, pp. 33–39, 2001.
[ 2 6 ] T .C .H a m i l t o n ,R .C .Y o u n g ,W .M .M c K o y ,e ta l . ,“ C h a r a c t e r -
ization of a human ovarian carcinoma cell line (NIH:OVCAR-
3) with androgen and estrogen receptors,” Cancer Research,
vol. 43, no. 11, pp. 5379–5389, 1983.
[27] T. Lindmo, E. Boven, F. Cuttitta, J. Fedorko, and P. A.
Bunn, “Determination of the immunoreactive fraction of
radiolabeled monoclonal antibodies by linear extrapolation to
binding at inﬁnite antigen excess,” Journal of Immunological
Methods, vol. 72, no. 1, pp. 77–89, 1984.
[28] J. Elgqvist, H. Andersson, T. B¨ ack, et al., “Fractionated
radioimmunotherapy of intraperitoneally growing ovarian
cancer in nude mice with 211At-MX35F(ab
 )2: therapeutic
eﬃcacy and myelotoxicity,” Nuclear Medicine and Biology, vol.
33, no. 8, pp. 1065–1072, 2006.
[29] H. Andersson, E. Cederkrantz, T. B¨ ack, et al., “Intraperitoneal
α-particle radioimmunotherapy of ovarian cancer patients:
pharmacokinetics and dosimetry of 211At-MX35F(ab
 )2—a
phase I study,” Journal of Nuclear Medicine, vol. 50, no. 7, pp.
1153–1160, 2009.